These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 24797423

  • 1. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW.
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.
    JAMA; 2016 Apr 26; 315(16):1715-25. PubMed ID: 27115376
    [Abstract] [Full Text] [Related]

  • 3. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C.
    Pediatr Allergy Immunol; 2007 Feb 26; 18(1):47-57. PubMed ID: 17295799
    [Abstract] [Full Text] [Related]

  • 4. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, Ljørring C.
    Ann Allergy Asthma Immunol; 2015 Feb 26; 114(2):134-40. PubMed ID: 25624131
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.
    J Allergy Clin Immunol; 2016 Dec 26; 138(6):1631-1638. PubMed ID: 27521719
    [Abstract] [Full Text] [Related]

  • 6. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J, Prenner BM, Bernstein DI, Lu S, Gawchik S, Berman G, Kaur A, Li Z, Nolte H.
    Ann Allergy Asthma Immunol; 2016 Jan 26; 116(1):59-65. PubMed ID: 26553448
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW, Virchow JC, Zieglmayer P, Ljørring C, Smith IM, Mosbech H.
    Expert Rev Clin Immunol; 2016 Aug 26; 12(8):805-15. PubMed ID: 27322777
    [Abstract] [Full Text] [Related]

  • 8. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W, Hernández MD, Cardona V, Smeenk F, Fogh BS, Calderon MA, de Blay F, Backer V.
    Int Arch Allergy Immunol; 2017 Aug 26; 174(1):35-44. PubMed ID: 28950268
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D, Konno A.
    J Allergy Clin Immunol; 2017 Jun 26; 139(6):1840-1848.e10. PubMed ID: 27864024
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct 26; 29(10):679-87. PubMed ID: 17129496
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials.
    Wongsa C, Phinyo P, Sompornrattanaphan M, Krikeerati T, Lumkul L, Thongngarm T.
    J Allergy Clin Immunol Pract; 2022 May 26; 10(5):1342-1355.e24. PubMed ID: 35181547
    [Abstract] [Full Text] [Related]

  • 15. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA, Casale TB, Nelson HS, Demoly P.
    J Allergy Clin Immunol; 2013 Dec 26; 132(6):1322-36. PubMed ID: 24139829
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma.
    Tanaka A, Tohda Y, Okamiya K, Azuma R, Terada I, Adachi M.
    J Allergy Clin Immunol Pract; 2020 Feb 26; 8(2):710-720.e14. PubMed ID: 31541768
    [Abstract] [Full Text] [Related]

  • 17. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.
    Respir Med; 2013 Sep 26; 107(9):1322-9. PubMed ID: 23886432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.